Selective intracellular vaporisation of antibody-conjugated phase-change nano-droplets in vitro

A. Ishijima, K. Minamihata, S. Yamaguchi, S. Yamahira, R. Ichikawa, E. Kobayashi, M. Iijima, Y. Shibasaki, T. Azuma, T. Nagamune, I. Sakuma

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

While chemotherapy is a major mode of cancer therapeutics, its efficacy is limited by systemic toxicities and drug resistance. Recent advances in nanomedicine provide the opportunity to reduce systemic toxicities. However, drug resistance remains a major challenge in cancer treatment research. Here we developed a nanomedicine composed of a phase-change nano-droplet (PCND) and an anti-cancer antibody (9E5), proposing the concept of ultrasound cancer therapy with intracellular vaporisation. PCND is a liquid perfluorocarbon nanoparticle with a liquid-gas phase that is transformable upon exposure to ultrasound. 9E5 is a monoclonal antibody targeting epiregulin (EREG). We found that 9E5-conjugated PCNDs are selectively internalised into targeted cancer cells and kill the cells dynamically by ultrasound-induced intracellular vaporisation. In vitro experiments show that 9E5-conjugated PCND targets 97.8% of high-EREG-expressing cancer cells and kills 57% of those targeted upon exposure to ultrasound. Furthermore, direct observation of the intracellular vaporisation process revealed the significant morphological alterations of cells and the release of intracellular contents.

Original languageEnglish
Article number44077
JournalScientific reports
Volume7
DOIs
Publication statusPublished - Mar 23 2017

All Science Journal Classification (ASJC) codes

  • General

Fingerprint Dive into the research topics of 'Selective intracellular vaporisation of antibody-conjugated phase-change nano-droplets in vitro'. Together they form a unique fingerprint.

Cite this